315 related articles for article (PubMed ID: 10741399)
1. IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic immunopathology.
Satoskar AR; Rodig S; Telford SR; Satoskar AA; Ghosh SK; von Lichtenberg F; David JR
Eur J Immunol; 2000 Mar; 30(3):834-9. PubMed ID: 10741399
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic efficacy of high-molecular-weight antigenic fractions of a recent clinical isolate of Leishmania donovani against visceral leishmaniasis.
Tripathi P; Gupta SK; Sinha S; Sundar S; Dube A; Naik S
Scand J Immunol; 2008 Nov; 68(5):492-501. PubMed ID: 18803606
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-27R (WSX-1/T-cell cytokine receptor) gene-deficient mice display enhanced resistance to leishmania donovani infection but develop severe liver immunopathology.
Rosas LE; Satoskar AA; Roth KM; Keiser TL; Barbi J; Hunter C; de Sauvage FJ; Satoskar AR
Am J Pathol; 2006 Jan; 168(1):158-69. PubMed ID: 16400019
[TBL] [Abstract][Full Text] [Related]
4. Lack of CXCR3 delays the development of hepatic inflammation but does not impair resistance to Leishmania donovani.
Barbi J; Oghumu S; Rosas LE; Carlson T; Lu B; Gerard C; Lezama-Davila CM; Satoskar AR
J Infect Dis; 2007 Jun; 195(11):1713-7. PubMed ID: 17471442
[TBL] [Abstract][Full Text] [Related]
5. The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice.
Lehmann J; Enssle KH; Lehmann I; Emmendörfer A; Lohmann-Matthes ML
J Interferon Cytokine Res; 2000 Jan; 20(1):63-77. PubMed ID: 10670653
[TBL] [Abstract][Full Text] [Related]
6. Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40.
Hernández MX; Barçante TA; Vilela L; Tafuri WL; Afonso LC; Vieira LQ
Immunol Lett; 2006 May; 105(1):38-47. PubMed ID: 16466810
[TBL] [Abstract][Full Text] [Related]
7. Experimental visceral leishmaniasis: production of interleukin 2 and interferon-gamma, tissue immune reaction, and response to treatment with interleukin 2 and interferon-gamma.
Murray HW; Stern JJ; Welte K; Rubin BY; Carriero SM; Nathan CF
J Immunol; 1987 Apr; 138(7):2290-7. PubMed ID: 3104456
[TBL] [Abstract][Full Text] [Related]
8. Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis.
Murray HW; Moreira AL; Lu CM; DeVecchio JL; Matsuhashi M; Ma X; Heinzel FP
J Infect Dis; 2003 Aug; 188(3):458-64. PubMed ID: 12870129
[TBL] [Abstract][Full Text] [Related]
9. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
Bhaumik SK; Naskar K; De T
Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
[TBL] [Abstract][Full Text] [Related]
10. Immunological responses of L. donovani infection in mice and significance of T cell in resistance to experimental leishmaniasis.
Rezai HR; Farrell J; Soulsby EL
Clin Exp Immunol; 1980 Jun; 40(3):508-14. PubMed ID: 6968259
[TBL] [Abstract][Full Text] [Related]
11. NK cell activation in visceral leishmaniasis requires TLR9, myeloid DCs, and IL-12, but is independent of plasmacytoid DCs.
Schleicher U; Liese J; Knippertz I; Kurzmann C; Hesse A; Heit A; Fischer JA; Weiss S; Kalinke U; Kunz S; Bogdan C
J Exp Med; 2007 Apr; 204(4):893-906. PubMed ID: 17389237
[TBL] [Abstract][Full Text] [Related]
12. The role of mannose receptor during experimental leishmaniasis.
Akilov OE; Kasuboski RE; Carter CR; McDowell MA
J Leukoc Biol; 2007 May; 81(5):1188-96. PubMed ID: 17261547
[TBL] [Abstract][Full Text] [Related]
13. Endogenous interleukin-18 is involved in immunity to Leishmania donovani but its absence does not adversely influence the therapeutic activity of sodium stibogluconate.
Mullen AB; Lawrence CE; McFarlane E; Wei XQ; Carter KC
Immunology; 2006 Nov; 119(3):348-54. PubMed ID: 16879623
[TBL] [Abstract][Full Text] [Related]
14. Role of L3T4+ and LyT-2+ cells in experimental visceral leishmaniasis.
Stern JJ; Oca MJ; Rubin BY; Anderson SL; Murray HW
J Immunol; 1988 Jun; 140(11):3971-7. PubMed ID: 3131421
[TBL] [Abstract][Full Text] [Related]
15. Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani.
Engwerda CR; Murphy ML; Cotterell SE; Smelt SC; Kaye PM
Eur J Immunol; 1998 Feb; 28(2):669-80. PubMed ID: 9521077
[TBL] [Abstract][Full Text] [Related]
16. Co-administration of IL-12 DNA with rORFF antigen confers long-term protective immunity against experimental visceral leishmaniaisis.
Tewary P; Saxena S; Madhubala R
Vaccine; 2006 Mar; 24(13):2409-16. PubMed ID: 16413950
[TBL] [Abstract][Full Text] [Related]
17. IL-2-stimulated splenocytes reduce infections by Leishmania donovani in vivo.
Olivier M; Eslami Z; Tanner CE
J Parasitol; 1996 Feb; 82(1):78-81. PubMed ID: 8627506
[TBL] [Abstract][Full Text] [Related]
18. The TGF-beta response to Leishmania chagasi in the absence of IL-12.
Wilson ME; Recker TJ; Rodriguez NE; Young BM; Burnell KK; Streit JA; Kline JN
Eur J Immunol; 2002 Dec; 32(12):3556-65. PubMed ID: 12516540
[TBL] [Abstract][Full Text] [Related]
19. TLR-mediated distinct IFN-γ/IL-10 pattern induces protective immunity against murine visceral leishmaniasis.
Paul J; Karmakar S; De T
Eur J Immunol; 2012 Aug; 42(8):2087-99. PubMed ID: 22622993
[TBL] [Abstract][Full Text] [Related]
20. Infections in immunocompetent and immune-deficient mice with promastigotes of a North American isolate of Leishmania infantum.
Rosypal AC; Zajac AM; Troy GC; Lindsay DS
Vet Parasitol; 2005 Jun; 130(1-2):19-27. PubMed ID: 15893066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
